Cerebral accumulation of amyloid A protein (AA) is characteristic of Alzheimer disease (AD). AA can be detected in cerebrospinal fluid and in plasma. Although plasma AA has been proposed as a marker of risk of AD, it is unknown how plasma levels relate to neuropathologic levels. We compared plasma levels of AA40 and AA42 obtained during life with biochemical and pathologic levels in frontal and temporal neocortex in 25 individuals (17 AD, 3 control, and 5 non-AD dementia) who died a median of 1 year after blood collection. Plasma levels of AA40 and AA42 were not associated with any of the brain measures, even after adjusting for age and interval between plasma collection and death. The APOE ?4 allele may modify the relationship between plasma AA42 and formic acid-extractable AA42, with an inverse correlation in APOE ?4 carriers and a positive correlation in those lacking APOE ?4. We conclude that plasma levels of AA40 and AA42 are not robust correlates of histologic or biochemically assessed amyloid burdens in brain, although the influence of the APOE genotype should be further explored.
INTRODUCTION
Cerebral accumulation of amyloid A protein (AA) is a characteristic pathologic feature of Alzheimer disease (AD). AA is produced by sequential A-and F-secretase processing of the amyloid precursor protein, resulting primarily in AA species ending at positions Val-40 (AA40) or Ala-42 (AA42). AA40 is the principal component of vascular amyloid, whereas AA42 aggregates more readily and is the initial AA species deposited in brain parenchyma (1Y4). Biochemically, AA40 and AA42 segregate into biochemical compartments (intracellular, membrane associated, extracellular soluble, and insoluble) defined by sequential extraction procedures (5, 6) . All biochemical and neuropathologic forms of AA are elevated in AD brain (6) . AA accumulation is initiated years before the onset of symptoms, which begin after a threshold of neuronal loss, synaptic loss, and neurofibrillary tangle formation. Therefore, markers of amyloid accumulation in the brain may be useful as antecedent or clinical diagnostic biomarkers of AD.
The development of sensitive ELISA-based assays has allowed detection of AA in cerebrospinal fluid (CSF) and plasma. CSF AA42 levels are consistently lower in AD, a finding attributed to depletion of the monomeric protein from the CSF during incorporation into oligomeric soluble and insoluble forms in the brain (7) . In part because of its availability, plasma AA has been studied as a marker of AD susceptibility, diagnosis, and treatment effects. Plasma total AA or AA42 is increased in cases of familial AD with presenilin or amyloid precursor protein mutations and in trisomy 21 (8Y10). Plasma AA levels were not consistently related to diagnosis in clinic-based cross-sectional studies of the typical late-onset form of AD (8, 9, 11Y15) . Although these studies have examined the clinical, demographic, biochemical, and genetic factors that influence plasma AA levels, no studies have investigated the fundamental question of how plasma levels relate to neuropathologic evidence of AD. To further elucidate the role of plasma AA as a potential biomarker for AD, we compared plasma AA levels during life with measures of cortical biochemical and neuropathologic AA accumulation in study patients who subsequently came to autopsy.
MATERIALS AND METHODS

Subjects
The study participants consisted of patients followed in the Massachusetts Alzheimer Disease Research Center from 1991 to 2005 who donated plasma samples for clinical studies and subsequently came to autopsy. As part of institutional review board-approved protocols, informed consent for plasma collection was obtained from the patients and caregivers by a staff physician; autopsy consent was obtained from the next of kin. Clinical diagnoses at the time of plasma collection were based on established criteria for mild cognitive impairment (16) , AD (17) , progressive supranuclear palsy (PSP) (18) , and primary progressive aphasia (19) .
Tissue Collection
At autopsy, coronal slices from one hemisphere were fresh-frozen between dry ice-cooled aluminum plates, and the opposite hemisphere was fixed in 10% buffered formalin with subsequent processing and paraffin embedding. Neuropathologic diagnoses of AD (20Y22), PSP (23), corticobasal degeneration (CBD) (24) , and amyotrophic lateral sclerosis were made according to established diagnostic criteria.
AA Immunostaining
Five-micrometer paraffin sections were deparaffinized in xylenes, rehydrated with graded alcohols, pretreated with 
Amyloid Burden Quantitation
To calculate the percentage of cortical area covered by AA40 and AA42 immunostaining (% AA40 burden and % AA42 burden, respectively), stained sections were placed under a light microscope (Leica Microsystems, Fairfax, VA) equipped with a digital camera linked to a computer running Bioquant software (R and M Biometrics, Nashville, TN). An 800-Km-wide rectangular area spanning all cortical layers in the mid-superior temporal sulcus and the frontal neocortex region were delineated as described previously (25). At least 10 counting frames of 500 Â 500 Km were systematically sampled over the delineated areas. The areas of all immunostained plaques were determined under 10x objective. The sum total of all plaque areas was divided by the total area of the counting frames to obtain the percentage of cortex covered by AA40 and AA42 immunoreactivity, respectively.
Biochemical Extraction
For biochemical analysis of AA, approximately 1-cm strips of cortex from frozen temporal (Brodmann areas 20, 21, and 22) and frontal neocortex (Brodmann areas 9 and 10) was carefully dissected from the underlying white matter. The tissue was homogenized in 14 KL/mg wet weight Tris buffer, pH 7.2 (50 mmol/L Tris, 200 mmol/L NaCl 2 , 2 mmol/L EDTA, 0.1% Triton X-100, and 2% protease-free bovine serum albumin [BSA]) with protease inhibitors (Complete; Roche, Indianapolis, IN). After centrifugation (15,000 rpm, 21,000 Â g, 4-C, 5 minutes), the supernatant was collected (Tris-soluble AA fraction). The pellet was homogenized in 8 KL/mg wet weight 70% formic acid (FA) and recentrifuged (22,000 rpm, 44,000 Â g, 4-C, 5 minutes), 
Plasma Pretreatment
Blood was collected in K-EDTA tubes, spun, and stored in 1-mL aliquots at j80-C. For ELISA, plasma samples were precleared with IgG1 J (Sigma, St. Louis, MO) cross-linked Sepharose beads to block cross-reaction of unidentified components of human plasma with the AA ELISA (9, 14) . 
AA ELISA
Homogenates and plasma samples (100 KL, in triplicate) were incubated in BNT77 (Takeda, Osaka, Japan)-coated wells containing 50 KL of buffer C for plasma and 25 KL of buffer C for brain homogenate (20 mmol/L PO 4 , 400 mmol/L NaCl, 2 mmol/L EDTA, 0.2% BSA, 10% BlockAce, and 0.076% CHAPS, pH 7.2) overnight at 4-C. The plates were washed four times with PBS, then reacted with horseradish peroxidase-conjugated detector antibodies (BA27 IgG2 mouse anti-AA40 1:1000 for homogenate, 1:5000 for plasma; BC05 IgG1 mouse anti-AA42 1:10,000Y0.5 Kg/mL; Takeda) in 75 KL of buffer D (20 mmol/L PO 4 , 400 mmol/L NaCl, 2 mmol/L EDTA, and 1% BSA, pH 7.0) for 3 h at room temperature. After 6 washes with PBS, horseradish peroxidase enzyme activity was measured using QuantaBlu Fluorogenic Substrate (Pierce, Rockford, IL) on a Wallac Victor V2 plate reader using a 320-nm excitation filter and 400-nm emission filter. Each plate contained known concentrations of human synthetic AA 1-40 and AA 1-42 (Bachem, King of Prussia, PA) in Tris or neutralized FA buffer to construct a log-log standard curve. These ELISAs can detect N-terminally truncated BACE-cleaved AA species (AA 11-40/42) as well as full-length AA (AA 1-40/42) but not >-secretase cleaved products (p3-AA 17-40/42) (26) .
Statistical Analysis
AD and non-AD cases were compared by the nonparametric Wilcoxon rank-sum test. Spearman correlations between each biochemical and neuropathologic measure were evaluated with plasma AA measures. Linear regression examined the association of the plasma AA measures with the biochemical and neuropathologic measures, adjusting for age, diagnosis, and time from plasma collection to autopsy.
RESULTS
Demographics
Matched plasma and brain samples were obtained from 25 research subjects. Plasma was collected from 24 days to There was no significant difference between the AD and non-AD groups in age at blood draw (p = 0.22), age at death (p = 0.21), or time from the blood draw to death (p = 0.41). An APOE ?4 allele was present in 53% of the AD patients and 25% of the non-AD patients (Table 1) .
AA Quantitation
Plasma AA40 levels were lower in AD than in non-AD cases (p = 0.05), whereas AA42 levels were similar. We surveyed a range of biochemical and pathologic AA measures in brain for correlation with plasma levels. These included AA40 and AA42 levels in soluble (Tris) and insoluble (FA) fractions of temporal and frontal neocortex and the deposited AA40 and AA42 burden in these same brain regions. All AA measures were elevated in the AD versus non-AD neocortex (p G 0.05, except p = 0.07 for temporal soluble [Tris] AA40) (Fig. 1) . As expected, AA42 burden tended to exceed AA40 burden; AA40 preferentially localized to plaque cores and amyloid angiopathy (Fig. 2) .
Correlation Between Plasma AA and Brain AA
We determined the Spearman correlation between the plasma and brain AA measures among all the cases (Table 2) and among the AD cases alone (Table 3) . Among all cases, the neuropathologic and brain biochemical measures of AA40 and of AA42 were intercorrelated. Plasma levels of AA40 and AA42 did not correlate with any of the brain measures ( Table 2 , Fig. 3 ).
Among the AD cases alone, the intercorrelation among the brain measures was weaker. Plasma AA42 was inversely correlated with frontal AA42 burden (p = 0.03) and frontal soluble (Tris) AA42, but not any other brain measures (Table 3 , Fig. 4) .
Regression analyses were also adjusted for age, interval between plasma draw and death, presence of cerebral amyloid angiopathy, and duration of illness. Even with these adjustments, no consistent correlations of plasma levels of AA40 and AA42 were found with the brain measures across the full sample. We were also interested in whether the APOE ?4 allele influenced the relation between plasma and brain AA. Although the individual correlations were not statistically significant, plasma AA42 tended to be inversely correlated with biochemical AA42 measures in the brain in APOE ?4 carriers (Spearman r = j0.12 to j0.53, n = 11), but positively correlated with biochemical brain AA42 measure in noncarriers (r = +0.26 to +0.53, n = 13) (Fig. 5) . In a linear regression model predicting plasma AA42, a test for interaction between FA temporal AA42 and APOE ?4 was significant (p G 0.05), adjusting for diagnosis, and an interaction between FA AA42 and APOE ?;4 was marginal (p = 0.07). This suggests that the APOE ?4 allele may modify the relationship between plasma and brain AA42 measures.
DISCUSSION
To assess the relevance of plasma AA levels as a reflection of pathologic changes in the AD brain, we compared plasma AA levels during life to postmortem brain AA measures in well-characterized and diverse neuropathologic specimens. As expected, biochemical and neuropathologic measures of AA40 and AA42 were elevated in AD brains relative to non-AD brains. However, across all cases, plasma AA levels were not associated with brain levels.
Plasma AA levels are probably modulated by peripheral and brain metabolism and clearance as well as by transport across brain, CSF, and vascular compartments. Although all forms of brain AA are elevated in AD, the weak correlations of the various brain AA measures in AD suggest that these may reflect distinct biochemical and morphologic pools of AA (6) . Furthermore, plasma AA levels and CSF AA levels are not correlated in AD (27) . It is not unexpected, therefore, that plasma AA and brain AA levels are not strongly correlated.
The results of our study should be interpreted in the context of the patient population, sample size, and study design. The number of patients in the study was small, with an approximately 80% power to detect a correlation of 0.54 or greater at > = 0.05. However, correlations were detected among the brain AA measures in the entire cohort. Although plasma was obtained from 1 to 3 years before death, plasma measures of AA tended to be relatively stable (28) . Our finding that the APOE genotype might alter the relationship between plasma and brain AA level is based on a small population and should be extended in further studies. If confirmed, it suggests that interpretation of plasma biomarkers would need to be adapted in light of other genetic factors.
There are several implications of these results to the use of plasma AA as a biomarker of AD. Plasma AA cannot reliably distinguish cases with prominent brain AA deposition (AD) from those without AA deposition (non-AD), limiting its usefulness as a diagnostic or predictive biomarker. The interesting inverse relation of plasma AA42 with some brain AA42 measures within the AD cases may be a peripheral reflection of low CSF AA42 in AD. Finally, the pathology of AD reflects the end stage of a pathophysiologic process beginning years before the onset of symptoms. If plasma AA is a risk factor for AD as is suggested in two longitudinal cohort studies (28) , the relevant AA levels may be those seen 5 to 20 years before death (29) .
